# US 2003/0228689 A1 · Antisense modulation of G protein-coupled receptor kinase 6 expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228689 A1
- Document ID: US20030228689A1
- Status: Published application
- Kind: A1
- Application number: 10/159,856
- Filed: 2002-05-31
- Published: 2003-12-11
- Earliest claimed: 2002-05-31
- Assignees: Isis Pharmaceuticals, Inc.
- Inventors: Susan M. Freier; Kenneth W. Dobie
- Web page: https://patentgrep.com/patent/US20030228689A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor kinase 6. Methods of using these compounds for modulation of G protein-coupled receptor kinase 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor kinase 6 are provided.

## Claims

### Claim 1

A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding G protein-coupled receptor kinase 6, wherein said compound specifically hybridizes with said nucleic acid molecule encoding G protein-coupled receptor kinase 6 and inhibits the expression of G protein-coupled receptor kinase 6.

### Claim 2 (depends on 1)

The compound of claim 1 which is an antisense oligonucleotide.

### Claim 3 (depends on 2)

The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 4 (depends on 3)

The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim 5 (depends on 2)

The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

### Claim 6 (depends on 5)

The compound of claim 5 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.

### Claim 7 (depends on 2)

The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

### Claim 8 (depends on 7)

The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

### Claim 9 (depends on 2)

The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

### Claim 10

A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding G protein-coupled receptor kinase 6.

### Claim 11 (depends on 1)

A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 12 (depends on 11)

The composition of claim 11 further comprising a colloidal dispersion system.

### Claim 13 (depends on 11)

The composition of claim 11 wherein the compound is an antisense oligonucleotide.

### Claim 14 (depends on 1)

A method of inhibiting the expression of G protein-coupled receptor kinase 6 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of G protein-coupled receptor kinase 6 is inhibited.

### Claim 15 (depends on 1)

A method of treating an animal having a disease or condition associated with G protein-coupled receptor kinase 6 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of G protein-coupled receptor kinase 6 is inhibited.

### Claim 16 (depends on 15)

The method of claim 15 wherein the disease or condition is rheumatoid arthritis.

### Claim 17 (depends on 15)

The method of claim 15 wherein the disease or condition is drug addiction.

### Claim 18 (depends on 15)

The method of claim 15 wherein the disease or condition is a disorder of uterine contractility.

### Claim 19 (depends on 15)

The method of claim 15 wherein the disease or condition is hypertension.

### Claim 20 (depends on 15)

The method of claim 15 wherein the disease or condition arises from aberrant hematopoiesis.
